Irbesartan (a comprehensive profile)

Darwish, Ibrahim A.; Darwish, Hany W.; Bakheit, Ahmed H.; Alkahtani, Hamad M.; Alanazi, Zahi Saad

doi:10.1016/bs.podrm.2020.07.004

Cited by 14 publications

(8 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…При подготовке данного обзора был проведен поиск отечественных и зарубежных публикаций в российских и международных системах поиска (PubMed, eLibrary и др. ), анализ информации в государственном реестре лекарственных средств (ГРЛС), а также в реестре фармацевтических субстанций и лекарственных средств [6].…”

Section: обзор литературыunclassified

“…В литературе много противоречивых данных об аффинности БРА, что объясняется использованием разных лабораторных моделей и других условий эксперимента [12]. Тем не менее, в настоящее время считается, что все БРА (или их активные метаболиты) конкурентно и необратимо связываются с рецептором, переводя его в неактивное состояние [6,13].…”

Section: фармакодинамика и эффективность ирбесартанаunclassified

“…Ирбесартан является селективным антагонистом AT 1 -рецептора и блокирует все эффекты ангиотензина II, опосредованные этими рецепторами, независимо от источника или пути синтеза ангиотензина II. В нескольких исследованиях была показана способность ирбесартана ингибировать прессорный ответ на экзогенный ангиотензин II у людей с нормальным АД [6,[14][15][16]. Ирбесартан ингибировал прессорное действие ангиотензина II до 100% на пике через 4 ч после приема внутрь в дозе 25-300 мг [6,15,16].…”

Section: фармакодинамика и эффективность ирбесартанаunclassified

“…В нескольких исследованиях была показана способность ирбесартана ингибировать прессорный ответ на экзогенный ангиотензин II у людей с нормальным АД [6,[14][15][16]. Ирбесартан ингибировал прессорное действие ангиотензина II до 100% на пике через 4 ч после приема внутрь в дозе 25-300 мг [6,15,16]. В двойном слепом, плацебо-контролируемом, рандомизированном четырехстороннем перекрестном исследовании степень и продолжительность блокады рецепторов ангиотензина II, индуцированной 150 мг ирбесартана, были значимо больше, чем при применении 50 мг лозартана или 80 мг валсартана [6,14].…”

Section: фармакодинамика и эффективность ирбесартанаunclassified

See 3 more Smart Citations

Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases

Rebrova¹,

Shikh²,

Ryazanovа³

2022

CPT

View full text Add to dashboard Cite

Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.

show abstract

Section: обзор литературыunclassified

Section: фармакодинамика и эффективность ирбесартанаunclassified

See 2 more Smart Citations

Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases

Rebrova¹,

Shikh²,

Ryazanovа³

2022

CPT

View full text Add to dashboard Cite

show abstract

“…We derive a new "LIM-pair" quadratic estimator for LIM lensing, relying on a pair of LIMs, from two lines X and Y emitted at the same redshift but with uncorrelated interloper foregrounds. This method is analogous in spirit to the gradient-cleaned estimators of CMB lensing [40,41]. We forecast the signalto-noise ratio for this estimator for one example line pair.…”

Section: Introductionmentioning

confidence: 99%

New probe of the high-redshift Universe: Nulling CMB lensing with interloper-free line intensity mapping pair lensing

2022

View full text Add to dashboard Cite

Intermediate redshifts between galaxy surveys and the cosmic microwave background (CMB) remain unexplored territory. Line intensity mapping (LIM) offers a way to probe the z 1 Universe, including the epoch of reionization and the dark ages. Via exact nulling of the lensing kernel, we show that LIM lensing, in combination with galaxy (resp., CMB) lensing, can uniquely probe the z 1 (resp., pre-reionization) Universe.However, LIM foregrounds are a key hurdle to this futuristic technique. While continuum foregrounds can be controlled by discarding modes perpendicular to the line of sight (low k modes), interloper foregrounds haven't been addressed in the context of LIM lensing. In this paper, we quantify the interloper bias to LIM lensing for the first time, and derive a "LIM-pair" estimator which avoids it exactly after cross-correlating with CMB lensing. This new quadratic lensing estimator works by combining two intensity maps in different lines, from the same redshift, whose interlopers are uncorrelated. As a result, this foreground avoidance method is robust to even large changes in the amplitude of the interloper power and non-Gaussianity. The cross-spectrum of the LIM-pair estimator with CMB lensing is thus robust to the currently large theoretical uncertainties in LIM modeling at high redshift.

show abstract

Utilization of erythrosine B in spectrofluorimetric quenching analysis of amlodipine and perindopril in pharmaceutical and biological matrices

et al. 2023

View full text Add to dashboard Cite

A spectrofluorimetric approach that is sensitive, simple, validated, and cost‐effective has been proposed for the estimation of amlodipine (AML) and perindopril (PER) in their bulk powders, pharmaceutical formulations, and spiked human plasma. The recommended approach utilized the quantitative quenching effect of the two cited drugs on the fluorescence intensity of erythrosine B, as a result of complex binary reactions among each drug with erythrosine B at pH 3.5 (Teorell and Stenhagen buffer). The quenching of erythrosine B fluorescence was recorded at 554 nm after excitation at 527 nm. The calibration curve was detected in the range 0.25–3.0 μg ml−1, with a correlation coefficient of 0.9996 for AML, and 0.1–1.5 μg ml−1, with a correlation coefficient of 0.9996 for PER. The established spectrofluorimetric approach was validated for the estimation of the cited drugs with high sensitivity regarding International Council on Harmonization guidelines. Therefore, the established approach could be utilized for quality control of the cited drugs in their pharmaceutical formulations.

show abstract

Irbesartan (a comprehensive profile)

Cited by 14 publications

References 71 publications

Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases

Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases

New probe of the high-redshift Universe: Nulling CMB lensing with interloper-free line intensity mapping pair lensing

Utilization of erythrosine B in spectrofluorimetric quenching analysis of amlodipine and perindopril in pharmaceutical and biological matrices

Contact Info

Product

Resources

About